Reduced tissue inhibitor of metalloproteinase‑2 expression is associated with advanced medullary thyroid carcinoma

  • Authors:
    • Simone Magagnin Wajner
    • Clarissa Capp
    • Beatriz Assis Brasil
    • Luise Meurer
    • Ana Luiza Maia
  • View Affiliations

  • Published online on: December 19, 2013     https://doi.org/10.3892/ol.2013.1767
  • Pages: 731-737
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Matrix metalloproteinases (MMPs) are enzymes for extracellular matrix remodeling that are involved in tumor growth, progression and metastasis. Among them, MMP‑9 has been implicated in tumor angiogenesis. Tissue inhibitor of matrix metalloproteinase (TIMP)‑2, a member of the family of MMP inhibitors, induces apoptosis and inhibits various stages of angiogenesis. Previous studies analyzing the expression of MMP‑9 and TIMP‑2 in medullary thyroid carcinoma (MTC) are scarce. The aims of the current study were to evaluate MMP‑9 and TIMP‑2 expression in MTC samples and correlate the results with clinical parameters. Paraffin‑embedded samples from 77 MTC patients were evaluated for expression by immunohistochemistry. The clinical data in medical records were retrospectively reviewed. In total, 77 patients aged 35.6±17.1 years were enrolled. Of these patients, 36 had hereditary disease (46.8%). Immunohistochemical staining for MMP‑9 and TIMP‑2 was detected in 89.6 and 93.5% of the samples, respectively. The expression of MMP‑9 was not found to correlate with clinical parameters, although, a trend toward a correlation between MMP‑9 and distant metastasis was observed (P=0.053). By contrast, TIMP‑2 staining was found to correlate with age at diagnosis (P=0.026) and negatively correlate with tumor size and tumoral stage (P=0.002 and P=0.001, respectively). Notably, the highest levels of TIMP‑2 expression were observed in patients with intrathyroidal disease. The MMP‑9 enzyme involved in extracellular matrix remodeling is overexpressed in MTC lesions and may contribute to tumor vascularization and growth. Reduced levels of TIMP‑2 expression may be implicated in tumor progression and spread of disease.
View Figures
View References

Related Articles

Journal Cover

2014-March
Volume 7 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wajner SM, Capp C, Brasil BA, Meurer L and Maia AL: Reduced tissue inhibitor of metalloproteinase‑2 expression is associated with advanced medullary thyroid carcinoma. Oncol Lett 7: 731-737, 2014.
APA
Wajner, S.M., Capp, C., Brasil, B.A., Meurer, L., & Maia, A.L. (2014). Reduced tissue inhibitor of metalloproteinase‑2 expression is associated with advanced medullary thyroid carcinoma. Oncology Letters, 7, 731-737. https://doi.org/10.3892/ol.2013.1767
MLA
Wajner, S. M., Capp, C., Brasil, B. A., Meurer, L., Maia, A. L."Reduced tissue inhibitor of metalloproteinase‑2 expression is associated with advanced medullary thyroid carcinoma". Oncology Letters 7.3 (2014): 731-737.
Chicago
Wajner, S. M., Capp, C., Brasil, B. A., Meurer, L., Maia, A. L."Reduced tissue inhibitor of metalloproteinase‑2 expression is associated with advanced medullary thyroid carcinoma". Oncology Letters 7, no. 3 (2014): 731-737. https://doi.org/10.3892/ol.2013.1767